India-made HPV vaccine to cost ₹200
CERVAVAC, India’s first indigenously developed vaccine to prevent cervical cancer, has been developed by SII
India's first indigenously developed vaccine to prevent cervical cancer, CERVAVAC, will likely cost ₹200-400 a shot and be commercially available later this year, said Adar Poonawalla, CEO, Serum Institute of India (SII), on the sidelines of a launch event here on Thursday.
CERVAVAC, developed by SII, was approved by the Drug Controller General of India in July. The event also underlined the role of the Indian government, particularly the Department of Biotechnology, in facilitating trials and investments in the vaccine candidate.
CERVAVAC is a quadrivalent vaccine, meaning it is effective against at least four variants of cancer-causing Human Papilloma Virus (HPV), and resulted from a partnership of DBT's Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation that supported Serum's development efforts.
CERVAVAC is also made using an approach that introduces VLP to stimulate an immune response from the body resulting in production of antibodies.
